Journal of Ophthalmology / 2019 / Article / Tab 4

Review Article

A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 4

Meta-analytic findings about postoperative best-corrected visual acuity compared to the baseline.

No. of studiesMean difference (95% CI)I2 (%) for heterogeneity

BCVA after 1 week
 IVR for NPDR without DME (LogMAR)1 [16]−0.06 (−0.18, 0.06)0.32Not applicable
 IVR for NPDR without DME (Snellen)2 [17, 19]0.04 (−0.04, 0.12)0.35500.16
 IVB for NPDR with DME (LogMAR)1 [21]−0.13 (−0.51, 0.25)0.50Not applicable
 IVR for NPDR with DME (Snellen)1 [18]0.16 (0.02, 0.30)0.02Not applicable
Total: (LogMAR)2 [16, 21]−0.07 (−0.18, 0.05)0.2500.73
Total: (Snellen)3 [1719]0.06 (−0.01, 0.14)0.11510.13

BCVA after 1 month
 IVB for NPDR without DME (LogMAR)1 [12]−0.24 (−0.34, −0.14)0.00001Not applicable
 IVR for NPDR without DME (LogMAR)1 [16]−0.07 (−0.17, 0.03)0.15Not applicable
 IVR for NPDR without DME (Snellen)1 [19]0.15 (0.09, 0.21)0.00001Not applicable
 IVB for NPDR with DME (LogMAR)2 [13, 21]−0.20 (−0.37, −0.03)0.0200.75
 IVR for NPDR with DME (Snellen)1 [18]0.19 (0.01, 0.37)0.04Not applicable
Total: (LogMAR)6 [1113, 15, 16, 21]−0.14 (−0.19, −0.09)0.0001500.07
Total: (Snellen)2 [18, 19]0.15 (0.10, 0.21)0.0000100.68

BCVA after 3 months
 IVB for NPDR without DME (LogMAR)1 [12]−0.04 (−0.14, 0.06)0.41Not applicable
 IVR for NPDR without DME (LogMAR)1 [16]−0.03 (−0.12, 0.06)0.50Not applicable
 IVR for NPDR without DME (Snellen)1 [19]0.20 (0.15, 0.25)0.00001Not applicable
 IVB for NPDR with DME (LogMAR)2 [13, 21]−0.13 (−0.24, −0.02)0.0200.91
 IVB for NPDR with DME (Snellen)1 [14]0.19 (0.02, 0.36)0.03Not applicable
 IVR for NPDR with DME (Snellen)1 [18]0.23 (0.05, 0.41)0.01Not applicable
Total: (LogMAR)6 [1113, 15, 16, 21]−0.06 (−0.11, −0.01)0.0200.58
Total: (Snellen)3 [14, 18, 19]0.20 (0.16, 0.25)0.0000100.94

BCVA after 6 months
 IVB for NPDR without DME (LogMAR)1 [12]0.00 (−0.10, 0.10)1.00Not applicable
 IVR for NPDR without DME (LogMAR)1 [16]−0.13 (−0.24, −0.02)0.02Not applicable
 IVR for NPDR without DME (Snellen)1 [17]0.15 (0.05, 0.25)0.005Not applicable
 IVB for NPDR with DME (Snellen)1 [14]0.26 (0.10, 0.42)0.002Not applicable
 IVR for NPDR with DME (Snellen)2 [18, 20]0.19 (0.10, 0.28)0.0000101.00
Total: (LogMAR)4 [11, 12, 15, 16]−0.07 (−0.11, −0.02)0.006210.29
Total: (Snellen)4 [14, 17, 18, 20]0.19 (0.12, 0.25)0.0000100.74

IVB = intravitreal bevacizumab; IVR = intravitreal ranibizumab; NPDR = nonproliferative diabetic retinopathy; BCVA = best-corrected visual acuity; DME = diabetic macular edema.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.